Combined effect of recombinant human bone morphogenetic protein-2 and low level laser irradiation on bisphosphonate-treated osteoblasts.
10.5125/jkaoms.2018.44.6.259
- Author:
Seok Young JEONG
1
;
Ji Un HONG
;
Jae Min SONG
;
In Ryoung KIM
;
Bong Soo PARK
;
Chul Hoon KIM
;
Sang Hun SHIN
Author Information
1. Department of Oral and Maxillofacial Surgery, School of Dentistry, Pusan National University, Yangsan, Korea. ssh8080@pusan.ac.kr
- Publication Type:Original Article
- Keywords:
Alendronate;
Osteoblasts;
Bone morphogenetic protein 2;
Low-level laser therapy
- MeSH:
Alendronate;
Bone Matrix;
Bone Morphogenetic Protein 2;
Cell Survival;
Collagen;
Humans*;
Low-Level Light Therapy;
Macrophage Colony-Stimulating Factor;
Osteoblasts*;
Osteoclasts;
Osteogenesis;
Osteoprotegerin;
Transforming Growth Factors
- From:Journal of the Korean Association of Oral and Maxillofacial Surgeons
2018;44(6):259-268
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVES: The purpose of this study was to evaluate the synergic effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) and low-level laser therapy (LLLT) on bisphosphonate-treated osteoblasts. MATERIALS AND METHODS: Human fetal osteoblast cells (hFOB 1.19) were cultured with 100 µM alendronate. Low-level Ga-Al-As laser alone or with 100 ng/mL rhBMP-2 was then applied. Cell viability was measured with MTT assay. The expression levels of receptor activator of nuclear factor kappa-B ligand (RANKL), macrophage colony-stimulating factor (M-CSF), and osteoprotegerin (OPG) were analyzed for osteoblastic activity inducing osteoclastic activity. Collagen type and transforming growth factor beta-1 were also evaluated for bone matrix formation. RESULTS: The results showed that rhBMP-2 and LLLT had a synergic effect on alendronate-treated osteoblasts for enhancing osteoblastic activity and bone matrix formation. Between rhBMP-2 and LLLT, rhBMP-2 exhibited a greater effect, but did not show a significant difference. CONCLUSION: rhBMP-2 and LLLT have synergic effects on bisphosphonate-treated osteoblasts through enhancement of osteoblastic activity and bone formation activity.
